Wells Fargo’s Alaunos Therapeutics TCRT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $543 | Buy |
190
+12
| +7% | +$36 | ﹤0.01% | 6390 |
|
|
2025
Q4 | $574 | Sell |
178
-5
| -3% | -$16 | ﹤0.01% | 6323 |
|
|
2025
Q3 | $441 | Hold |
183
| – | – | ﹤0.01% | 6302 |
|
|
2025
Q2 | $888 | Sell |
183
-33
| -15% | -$99 | ﹤0.01% | 6322 |
|
|
2025
Q1 | $318 | Sell |
216
-61
| -22% | -$100 | ﹤0.01% | 6302 |
|
|
2024
Q4 | $528 | Sell |
277
-96
| -26% | -$213 | ﹤0.01% | 6307 |
|
|
2024
Q3 | $1.2K | Sell |
373
-68
| -15% | -$244 | ﹤0.01% | 6106 |
|
|
2024
Q2 | $3.08K | Sell |
441
-273
| -38% | -$3.26K | ﹤0.01% | 5950 |
|
|
2024
Q1 | $12.9K | Sell |
714
-17
| -2% | -$340 | ﹤0.01% | 5692 |
|
|
2023
Q4 | $7.76K | Sell |
731
-35
| -5% | -$422 | ﹤0.01% | 5893 |
|
|
2023
Q3 | $15.2K | Sell |
766
-204
| -21% | -$8.79K | ﹤0.01% | 5692 |
|
|
2023
Q2 | $74.2K | Buy |
970
+234
| +32% | +$18.9K | ﹤0.01% | 5218 |
|
|
2023
Q1 | $69.6K | Buy |
736
+62
| +9% | +$5.9K | ﹤0.01% | 4991 |
|
|
2022
Q4 | $65.6K | Buy |
674
+86
| +15% | +$12.5K | ﹤0.01% | 4744 |
|
|
2022
Q3 | $150K | Buy |
588
+236
| +67% | +$68.6K | ﹤0.01% | 4394 |
|
|
2022
Q2 | $66K | Sell |
352
-786
| -69% | -$75.1K | ﹤0.01% | 4886 |
|
|
2022
Q1 | $111K | Sell |
1,138
-976
| -46% | -$125K | ﹤0.01% | 5275 |
|
|
2021
Q4 | $345K | Buy |
2,114
+1,548
| +273% | +$340K | ﹤0.01% | 4954 |
|
|
2021
Q3 | $154K | Sell |
566
-502
| -47% | -$154K | ﹤0.01% | 5209 |
|
|
2021
Q2 | $423K | Sell |
1,068
-211
| -16% | -$98.5K | ﹤0.01% | 4709 |
|
|
2021
Q1 | $690K | Sell |
1,279
-870
| -40% | -$542K | ﹤0.01% | 4495 |
|
|
2020
Q4 | $813K | Buy |
2,149
+258
| +14% | +$103K | ﹤0.01% | 4180 |
|
|
2020
Q3 | $715K | Buy |
1,891
+185
| +11% | +$81.7K | ﹤0.01% | 4099 |
|
|
2020
Q2 | $839K | Buy |
1,706
+663
| +64% | +$296K | ﹤0.01% | 3948 |
|
|
2020
Q1 | $383K | Sell |
1,043
-10
| -0.9% | -$5.17K | ﹤0.01% | 4238 |
|
|
2019
Q4 | $746K | Buy |
1,053
+255
| +32% | +$175K | ﹤0.01% | 4062 |
|
|
2019
Q3 | $512K | Sell |
798
-93
| -10% | -$73.8K | ﹤0.01% | 4359 |
|
|
2019
Q2 | $779K | Buy |
891
+147
| +20% | +$101K | ﹤0.01% | 4073 |
|
|
2019
Q1 | $430K | Buy |
744
+10
| +1% | +$4.18K | ﹤0.01% | 4426 |
|
|
2018
Q4 | $205K | Sell |
734
-26
| -3% | -$10.3K | ﹤0.01% | 4885 |
|
|
2018
Q3 | $365K | Sell |
760
-1,237
| -62% | -$530K | ﹤0.01% | 4659 |
|
|
2018
Q2 | $905K | Buy |
1,997
+323
| +19% | +$205K | ﹤0.01% | 4066 |
|
|
2018
Q1 | $985K | Buy |
1,674
+344
| +26% | +$214K | ﹤0.01% | 3931 |
|
|
2017
Q4 | $826K | Sell |
1,330
-124
| -9% | -$89.1K | ﹤0.01% | 4048 |
|
|
2017
Q3 | $1.34M | Buy |
1,454
+67
| +5% | +$59.5K | ﹤0.01% | 3628 |
|
|
2017
Q2 | $1.29M | Buy |
1,387
+58
| +4% | +$56.9K | ﹤0.01% | 3533 |
|
|
2017
Q1 | $1.26M | Buy |
1,329
+69
| +5% | +$64.2K | ﹤0.01% | 3570 |
|
|
2016
Q4 | $1.01M | Buy |
1,260
+214
| +20% | +$193K | ﹤0.01% | 3688 |
|
|
2016
Q3 | $883K | Buy |
1,046
+14
| +1% | +$11.3K | ﹤0.01% | 3562 |
|
|
2016
Q2 | $849K | Buy |
1,032
+132
| +15% | +$144K | ﹤0.01% | 3587 |
|
|
2016
Q1 | $1M | Sell |
900
-224
| -20% | -$229K | ﹤0.01% | 3418 |
|
|
2015
Q4 | $1.4M | Buy |
1,124
+175
| +18% | +$289K | ﹤0.01% | 3255 |
|
|
2015
Q3 | $1.28M | Buy |
949
+188
| +25% | +$310K | ﹤0.01% | 3330 |
|
|
2015
Q2 | $1.37M | Buy |
761
+345
| +83% | +$536K | ﹤0.01% | 3365 |
|
|
2015
Q1 | $672K | Buy |
416
+252
| +154% | +$373K | ﹤0.01% | 3778 |
|
|
2014
Q4 | $125K | Buy |
164
+13
| +9% | +$6.9K | ﹤0.01% | 4655 |
|
|
2014
Q3 | $60K | Sell |
151
-62
| -29% | -$29.9K | ﹤0.01% | 4868 |
|
|
2014
Q2 | $128K | Buy |
213
+80
| +60% | +$44.5K | ﹤0.01% | 4586 |
|
|
2014
Q1 | $91K | Buy |
133
+94
| +241% | +$63K | ﹤0.01% | 4694 |
|
|
2013
Q4 | $25K | Hold |
39
| – | – | ﹤0.01% | 4959 |
|
|
2013
Q3 | $23K | Sell |
39
-96
| -71% | -$43.3K | ﹤0.01% | 4918 |
|
|
2013
Q2 | $43K | Buy |
+135
| New | +$37.5K | ﹤0.01% | 4652 |
|
Other funds holding TCRT
VFT
VCM
HF
XT
Wells Fargo's TCRT Position: Q1 2026 in Review
Wells Fargo increased its Alaunos Therapeutics (TCRT) stake by 6.7% in Q1 2026, buying an estimated $36 and bringing the position to 190 shares worth $543. The position accounts for ﹤0.01% of the portfolio, ranked #6390.
Wells Fargo first reported a position in TCRT in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.4M in Q4 2015. 29 funds tracked by Wall St. Rank hold TCRT as of Q1 2026.
- Wells Fargo held 190 shares of Alaunos Therapeutics worth $543 as of Q1 2026.
- Wells Fargo bought 12 Alaunos Therapeutics shares in Q1 2026, an estimated $36.
- Alaunos Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6390 holding.
- Wells Fargo first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Wells Fargo's Alaunos Therapeutics position peaked at $1.4M in Q4 2015.
- 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.